TIAPROFENIC ACID

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H12O3S
Molecular Weight	260.308
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2

InChI

InChIKey=GUHPRPJDBZHYCJ-UHFFFAOYSA-N

InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C14H12O3S
Molecular Weight	260.308
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b

Tiaprofenic acid is a non-steroidal, anti-inflammatory, analgesic compound, which nonselectively inhibits cyclooxygenase protein. Tiaprofenic acid was approved in Europe for the symptomatic relief of arthritis, ankylosing spondylitis and other inflammatory-rheumatic disorders as well as the painful conditions after injury.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cyclooxygenase 89 Target ID: CHEMBL2094253 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17652824	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Arthritis 87 Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b	Palliative	Approved 8583	SURGAM Approved Use Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.
Pain after injury 2 Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b	Primary	Approved 8583	SURGAM Approved Use Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.
Soft-tissue rheumatic conditions 2 Sources: https://mein.sanofi.de/produkte/Surgam/Downloads?id=d7a43169-0340-476a-a43c-1871c227d63b	Palliative	Approved 8583	SURGAM Approved Use Symptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury.

C_max

Value	Dose	Co-administered	Analyte	Population
22 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
21.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
20.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.55 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8864796/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN
7.4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
7.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
11.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
8.78 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
76.71 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
65.53 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
77.25 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
79.6 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
35.33 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8864796/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN
37.7 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
35.8 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
44.3 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
39.3 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.77 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.47 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3582474/	200 mg 3 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8864796/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN
2.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
2.36 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN
2.35 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1748142/	3 mg/kg single, intragastric dose: 3 mg/kg route of administration: Intragastric experiment type: SINGLE co-administered: THIOPENTAL	THIOPENTAL	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
2.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/301929/		TIAPROFENIC ACID serum	Homo sapiens
1.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TIAPROFENIC ACID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4067848/	200 mg 3 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TIAPROFENIC ACID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3% OTHER https://www.medicines.org.uk/emc/product/2256#PHARMACOKINETIC_PROPS		TIAPROFENIC ACID plasma	Homo sapiens

Doses

Dose	Population	Adverse events
2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6333878/	healthy, ADOLESCENT Health Status: healthy Age Group: ADOLESCENT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6333878/	Sources: https://pubmed.ncbi.nlm.nih.gov/6333878/
400 mg 3 times / day multiple, oral Highest studied dose Dose: 400 mg, 3 times / day Route: oral Route: multiple Dose: 400 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8612471/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8612471/	Sources: https://pubmed.ncbi.nlm.nih.gov/8612471/
300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/	Disc. AE: Chronic interstitial cystitis... AEs leading to discontinuation/dose reduction: Chronic interstitial cystitis (grade 3) Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/
300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	Disc. AE: Anorexia, Alkaline phosphatase increased... Other AEs: Lethargy... AEs leading to discontinuation/dose reduction: Anorexia Alkaline phosphatase increased ALT increased GGT increased Other AEs: Lethargy Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/

AEs

AE	Significance	Dose	Population
Chronic interstitial cystitis	grade 3 Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/10319030/
Lethargy		300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/
ALT increased	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/
Alkaline phosphatase increased	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/
Anorexia	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/
GGT increased	Disc. AE	300 mg 2 times / day multiple, oral Recommended Dose: 300 mg, 2 times / day Route: oral Route: multiple Dose: 300 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2870297/

PubMed

Title	Date	PubMed
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.	2015-01-05	25455453
Enhancement of antinociception by coadministration of minocycline and a non-steroidal anti-inflammatory drug indomethacin in naïve mice and murine models of LPS-induced thermal hyperalgesia and monoarthritis.	2010-12-01	21122103
The effect of terpenes on percutaneous absorption of tiaprofenic acid gel.	2010-11	21116781
Hemorrhagic cystitis: A challenge to the urologist.	2010-04	20877590
Single dose oral tiaprofenic acid for acute postoperative pain in adults.	2009-10-07	19821426
Contact dermatitis due to topical drugs.	2009-10	19834431
Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.	2009-09	19740398
Photodegradation mechanism of nonsteroidal anti-inflammatory drugs containing thiophene moieties: suprofen and tiaprofenic acid.	2009-08-13	19719267
An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model.	2009-07-22	19624842
Systematic review of the management of canine osteoarthritis.	2009-04-04	19346540
Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial.	2009	20015358
The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery.	2008-10-31	18972594
Direct enantioselective HPLC monitoring of lipase-catalyzed kinetic resolution of tiaprofenic acid in nonstandard HPLC organic solvents.	2008-08	18246593
The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers.	2008-04-01	18359332
Cholesterol-diaryl ketone stereoisomeric dyads as models for "clean" type I and type II photooxygenation mechanisms.	2008-03-07	18292877
Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis.	2008	19007428
Acute NSAID-related transmural duodenitis and extensive duodenal ulceration.	2007-11	18158085
The pK(a) Distribution of Drugs: Application to Drug Discovery.	2007-09-17	19812734
Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review.	2007-07	17415595
Upper gastrointestinal complications associated with NSAIDs in children.	2007-04-06	17582320
Activity and potential role of licofelone in the management of osteoarthritis.	2007	18044077
Use of the yeast Saccharomyces cerevisiae as a pre-screening approach for assessment of chemical-induced phototoxicity.	2006-09	16497474
[Patterns of non steroidal anti-inflammatory drug use in ambulatory care].	2006-08-05	16886702
In vitro interactions of captopril with NSAID's.	2006-07	16935827
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population.	2005-11-29	16316472
Effects of co-administered dexamethasone and diclofenac potassium on pain, swelling and trismus following third molar surgery.	2005-11-07	16274480
The modulation of intra-articular inflammation, cartilage matrix and bone loss in mono-articular arthritis induced by heat-killed Mycobacterium tuberculosis.	2005	16259721
Risk of breast cancer among users of aspirin and other anti-inflammatory drugs.	2004-08-02	15226764
Evaluation of balhimycin as a chiral selector for enantioresolution by capillary electrophoresis.	2004-08	15351999
Vehicle effects on in vitro release of tiaprofenic acid from different topical formulations.	2004-07	15231433
Thin layer chromatographic resolution of some 2-arylpropionic acid enantiomers using L-(-)-serine, L-(-)-threonine and a mixture of L-(-)-serine and L-(-)-threonine-impregnated silica gel as stationary phases.	2003-07	12884398
The stereospecificity of flobufen metabolism in isolated guinea pig hepatocytes.	2003-06-05	12791169
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study.	2003-06-02	12771981
Spectrum of cross-photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non-benzophenone-containing molecules.	2003-03	12755728
Indomethacin-induced morphologic changes in the rat urinary bladder epithelium.	2003-01	12559315
The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety.	2002-12-27	12505292
Fixed drug eruption due to tiaprofenic acid.	2002-12	19753743
[Photocontact dermatitis due to ketoprofen and photosensitization to tetrachlorosalicylanide and to Fenticlor(R)].	2002-10	12442124
Use of the photo-micronucleus assay in Chinese hamster V79 cells to study photochemical genotoxicity.	2002-08-26	12160891
Differential effects of nonsteroidal antiinflammatory drugs on the IL-1 altered expression of plasminogen activators and plasminogen activator inhibitor-1 by articular chondrocytes.	2002-08	12234061
[Results of a French nationwide survey of cutaneous side effects of ketoprofen gel reported between September 1996 and August 2000].	2002-07-02	12090148
Do NSAIDs affect the progression of osteoarthritis?	2002-06	12083420
[Cross-reaction potentials of ketoprofen].	2002-05-12	12063858
Experimental study on phototoxicity and the photosensitization potential of ketoprofen, suprofen, tiaprofenic acid and benzophenone and the photocross-reactivity in guinea pigs.	2002-04	12147041
[Tuberculous osteitis of the malar bone].	2002	12616953
[Photoaggravated contact allergy and contact photoallergy caused by ketoprofen: 19 cases].	2001-10	11907961
Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans.	1993-04	8517101
Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis.	1993-04	8462374
Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs.	1993-01	8423545
Hepatotoxicity to several nonsteroidal anti-inflammatory drugs with diclofenac induced histological changes.	1992-03	1582111

Patents

Sample Use Guides

In Vivo Use Guide

The recommended daily dose range for adults is 600 mg tiaprofen acid per day divided into 2 doses.

Route of Administration: Oral

In Vitro Use Guide

Human osteoarthritic cartilage was treated with therapeutic doses of tiaprofenic acid (26 micrograms/ml; 2.6 micrograms/ml) in order to test the effect of the drug on the proteoglycan metabolism (catabolism and synthesis) and chondrocyte ultrastructure. The drug suppresed the proteoglycan metabolism by 38%.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:30 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:30 GMT 2025`
Record UNII	1LS1T6R34C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SURGAM

Preferred Name

English

TIAPROFENIC ACID

Official Name

English

TIAPROFEN

Brand Name

English

Tiaprofenic acid [WHO-DD]

Common Name

English

TIAPROFENATE

Common Name

English

tiaprofenic acid [INN]

Common Name

English

5-BENZOYL-.ALPHA.-METHYL-2-THIOPHENEACETIC ACID

Systematic Name

English

TIAPROFENIC ACID [MI]

Common Name

English

RU-15060

Code

English

TIAPROFENIC ACID [MART.]

Common Name

English

TIAPROFENIC ACID [JAN]

Common Name

English

TIAPROFENIC ACID [EP IMPURITY]

Common Name

English

TIAPROFENIC ACID [EP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM01AE11